Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Aviano – page 15

213 clinical trials in Aviano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Aviano at a glance
213
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

213 trials in Aviano

Open in trial search

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Follicular lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Follicular Lymphoma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not recruiting

Study on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

HER2 positive breast cancer

Not recruiting

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab
  • Sponsor:Novartis Pharma AG

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ETOP IBCSG Partners Foundation

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not recruiting

Study Comparing Selpercatinib with a Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer+2

Not recruiting

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Aviano

What the registry says about research in the country

01 Lung Cancer Research

Innovative trials exploring new treatment combinations for non-small cell lung cancer (NSCLC), including studies of novel immunotherapy approaches and targeted therapies. Research focuses on improving outcomes for patients with advanced stages of the disease.

  • Immunotherapy combinations
  • Maintenance therapy strategies
  • Targeted molecular treatments
02 Breast Cancer Studies

Clinical investigations targeting hormone receptor-positive and triple-negative breast cancers, evaluating novel therapeutic combinations and treatment strategies for both early-stage and metastatic disease.

  • Advanced/metastatic treatments
  • Hormone therapy combinations
  • Targeted therapies
03 Colorectal Cancer Trials

Research examining innovative approaches for metastatic colorectal cancer, including studies of targeted therapies and immunotherapy combinations. Focus on personalized treatment strategies based on molecular profiles.

  • Molecular-targeted therapies
  • Immunotherapy approaches
  • Combination treatments
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.